Ko 2005

Methods	Country: Hong Kong Setting/Design: Teaching hospitals Time frame: NS Randomisation method: NS Blinding ‐ Participants: No ‐ Investigators: No ‐ Outcome assessors: No ‐ Data analysis: No Intention‐to‐treat: Yes Follow‐up period: 1 year Loss to follow‐up: 1
Participants	Inclusion criteria DM: Type 2 Normal renal function or early stage nephropathy Enalapril group Number: 20 Age: 59.7 (11.8) Sex (M/F): 9/13 Valsartan group Number: 22 Age: 62.1 (10.5) Sex (M/F): 12/8 Exclusion criteria Uncontrolled hypertension (sitting BP > 200/115 mm Hg) History of MI CVA Uncontrolled CHF within the previous 6 months Significant renal impairment (SCr > 150 µmol/L)
Interventions	Enalapril group 5‐10 mg/d Valsartan group 80‐160 mg/d Co‐interventions Other antihypertensive agents
Outcomes	BP AER
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear